Affinivax grabs $120m Series B

Affinivax Inc, a technology platform provider for vaccines and immunotherapies, has closed $120 million in Series B financing.

Affinivax Inc, a technology platform provider for vaccines and immunotherapies, has closed $120 million in Series B financing. Viking Global Investors led the round with participation from Bain Capital Life Sciences and Ziff Capital Partners.

Source: Press Release